Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Problems in dealing with missing data and informative censoring in clinical trials.

Weichung Shih1

  • 1Division of Biometrics, University of Medicine and Dentistry of New Jersey School of Public Health, New Brunswick, New Jersey, USA. shihwj@umdnj.edu

Current Controlled Trials in Cardiovascular Medicine
|May 3, 2002
PubMed
Summary

Clinical trial missing data can bias results. Strategies include reporting dropouts, sensitivity analyses, minimizing patient dropout, collecting post-dropout data, and considering dropout as an endpoint.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.

Oncotarget·2023
Same author

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.

Frontiers in oncology·2023
Same author

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.

Future oncology (London, England)·2022
Same author

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.

European journal of medical research·2022
Same author

Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience.

Clinical lymphoma, myeloma & leukemia·2020
Same author

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.

Frontiers in oncology·2020

Area of Science:

  • Clinical Research
  • Biostatistics

Background:

  • Missing data is a common challenge in clinical trials, arising when participants withdraw before study completion.
  • This incomplete data can introduce bias into statistical analyses of trial outcomes.

Purpose of the Study:

  • To address the pervasive issue of missing data in clinical trials.
  • To propose practical recommendations for managing and mitigating the impact of participant dropouts.

Main Methods:

  • Review of common issues and consequences of missing data in clinical trial analysis.
  • Formulation of a multi-pronged strategy for handling missing data.

Main Results:

  • No single method universally resolves missing data; bias is a significant concern.

Related Experiment Videos

  • Recommended strategies include transparent reporting of dropout reasons, sensitivity analyses, proactive dropout minimization, post-dropout data collection, and treating dropout as a key endpoint.

    • Conclusions:

    • Effective management of missing data requires a comprehensive approach, integrating design, monitoring, and analysis.
    • Implementing these recommendations can improve the validity and reliability of clinical trial findings.